|Bid||0.00 x 900|
|Ask||11.21 x 800|
|Day's Range||10.26 - 10.95|
|52 Week Range||10.10 - 16.77|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||23.00|
Immunome Reports Third Quarter 2020 Financial Results and Significant Progress
Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics, with a focus on oncology and infectious diseases, including COVID-19, today announced the full exercise of the underwriters' option to purchase an additional 487,500 shares of common stock at the public offering price of $12.00 per share, resulting in additional gross proceeds of approximately $5.9 million, in connection with the Company’s previously announced initial public offering of common stock. After giving effect to the full exercise of the over-allotment option, the total number of shares sold by Immunome in the initial public offering was 3,737,500 shares and the gross proceeds were approximately $44.9 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. All of the shares were sold by Immunome. Immunome’s common stock began trading on the Nasdaq Capital Market on October 2, 2020, under the ticker symbol "IMNM".
Shares of Academy Sports & Outdoors may have dropped below their $13 initial public offering price on their first day of trading, but CEO Ken Hicks is still excited that the sporting goods discount store chain went public. The next steps for the Katy, Texas, retailer include paying down its $1.4 billion in debt, adding more stores, and giving people more of a reason to come into their existing 259 stores, said Hicks, who is also Academy’s (ticker: ASO) chairman and president. This is good for Academy Sports, which sells outdoor sporting equipment—such as tents, kayaks, and hiking backpacks—in addition to athletic gear and hunting clothing and gear.